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Abstract The objective of this review is to summarize
recent scientific and medical literature regarding che-
moresponse assays or chemotherapy sensitivity and resis-
tance assays (CSRAs), specifically as applied to epithelial
ovarian cancer. A total of sixty-seven articles, identified
through PubMed using the key words ‘‘in vitro chemore-
sponse assay,’’ ‘‘chemo sensitivity resistance assay,’’
‘‘ATP,’’ ‘‘HDRA,’’ ‘‘EDR,’’ ‘‘MiCK,’’ and ‘‘ChemoFx,’’
were reviewed. Recent publications on marker validation,
including relevant clinical trial designs, were also included.
Recent CSRA research and clinical studies are outlined in
this review. Published findings demonstrate benefits
regarding patient outcome with respect to recent CSRAs.
Specifically, analytical and clinical validations, as well as
clinical utility and economic benefit, of the most common
clinically used CSRA in the United States support its use to
aid in making effective, individualized clinical treatment
selections for patients with ovarian cancer.
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Ovarian cancer
Ovarian cancer is the most lethal and second most common
gynecologic malignancy in the United States, with an
estimated 21,980 new cases and 14,270 deaths expected in
2014 [1]. First progression typically occurs within
18 months, and overall survival (OS) is typically\4 years
[2–5]. Most patients are present with advanced disease, and
the current standard of care in the primary setting is sur-
gical debulking followed by platinum-based chemotherapy.
Ovarian cancer is a heterogeneous disease with respect
to histopathology, molecular biology, and clinical outcome,
suggesting that a single standard treatment is unlikely to
benefit all patients. Histologically, most ovarian cancer
arises from the distal fallopian tube or ovarian surface, and
the majority of these epithelial ovarian cancers (EOC) are
serous/papillary pathological subtype, followed by endo-
metrioid, mucinous, clear cell, and undifferentiated. These
different subtypes—together with other clinical factors
including age, performance status, FIGO stage, differenti-
ation, ascites presence, and surgical debulking status—are
important prognostic factors. Recent studies examined
ovarian cancer heterogeneity at the molecular level. The
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Cancer Genome Atlas project found that more than 30
growth-stimulating genes were altered across different
ovarian cancer subtypes. These alterations included: PI3K
pathway activation, BRCA1 or BRCA2 mutations, other
DNA repair defects and varied expression status of ER,
cyclin E2, and kit [6]. This molecular heterogeneity may be
linked to clinical heterogeneity, such as histological sub-
type presentation, disease prognosis, and chemotherapy
efficacy.
Carboplatin/paclitaxel has been widely accepted as the
standard of care in treating primary EOC for nearly two
decades [2–5]. Multiple alternate regimens have been
investigated, most of them based on the platinum/taxane
standard, but augmented with additional chemotherapies
and/or altered sequencing (Table 1) [2–5]. Many studies
have randomized patients across various regimens in an
effort to identify regimens superior to the carboplatin/
paclitaxel standard. These studies have consistently dem-
onstrated remarkably similar progression-free survival
(PFS) and OS between the standard of care and the various
alternates, highlighting the therapeutic equivalence of the
various regimens and the associated empiric treatment
ambiguity.
For patients with recurrent, persistent, or progressive
disease, chemotherapy choice is currently based, in part, on
the duration and type of response to initial therapy. For
platinum-sensitive disease [progression-free interval (PFI)
C6 months from the end of platinum/taxane therapy], a
platinum-based combination regimen is usually empirically
selected. For platinum-resistant disease (PFI \6 months),
physicians empirically select from an array of non-plati-
num regimens, including pegylated liposomal doxorubicin
(PLD), topotecan, gemcitabine, etoposide, taxanes, and
targeted therapies, all of which have been evaluated and
demonstrated to be clinically equivalent and acceptable for
use in this patient population [7].
While marker identification and development in ovarian
cancer is generally limited to early detection, monitoring
progression, or detecting recurrence, there are some
encouraging preliminary studies linking markers with drug
response, thereby demonstrating early potential for
informing effective individualized chemotherapy selection.
For example, expression of Copper importers/exporters,
ERCC1, Tau, GST-Pi, MLH1, and XIAP, and mutations of
MLH1, BRCA1/BRCA2, and p53 have been linked to
platinum response, and expression of TGFBI, Survivin, and
mutation of tubulin are associated with response to pac-
litaxel [8–21]. However, none of these biomarkers have
demonstrated sufficient clinical validation required to
inform clinical treatment decisions.
Chemoresponse assays: a panel of treatment response
markers
The National Institutes of Health (NIH) Biomarkers Defi-
nitions Working Group, which includes leaders in the field
from the Food and Drug Administration (FDA), NIH,
academia and industry, defines a marker as ‘‘a character-
istic that is objectively measured and evaluated as an
Table 1 Patient characteristics of control arm and assay-informed arm cohorts










Number of patients 783 1,308 1,282 4,312 192
Median age 57 60 59 59 59
Pathological subtype Serous/papillary 70 % 71 % 73 % 80 % 71 %
Other 30 % 29 % 27 % 20 % 29 %
FIGO stage distribution Stage I \1 % \1 %
Stage II 8 % 9 % 9 %
Stage III 75 % 74 % 74 % 85 % 84 %
Stage IV 17 % 17 % 17 % 15 % 16 %
Debulking status Optimal 63 % 67 % 68 % 68 % 52 %

















C carboplatin, P paclitaxel, G gemcitabine, D doxorubicin, E epirubicin, T topotecan, Cis cisplatin
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indicator of normal biologic processes, pathogenic pro-
cesses, or pharmacologic responses to a therapeutic inter-
vention’’ [22]. A marker was similarly described by Hayes
et al. as ‘‘a molecular, cellular, tissue, or process-based
alteration that provides indication of current, or more
importantly, future behavior of a cancer’’ [23].
A chemoresponse assay reports a panel of markers
characterizing a tumor’s response to multiple chemother-
apy agents. Each of the multiple chemotherapy assay
results reported is a singular marker associated with a
distinct treatment. Such assays provide tumor response
information aimed at aiding in the selection of effective,
individualized treatment regimens. Chemoresponse assays
provide the same utility as other treatment markers that are
associated with patient outcome when the given marker’s
associated treatment is clinically administered (e.g., KRAS
and cetuximab/panitumumab, EGFR and erlotinib, Her2
and trastuzumab). Chemoresponse assays are generally
based on phenotypic rather than molecular characteriza-
tion, thus enabling assays to simultaneously report multiple
treatment markers, each associated with a distinct treat-
ment, for a given patient [24].
The concept of a chemoresponse assay or chemotherapy
sensitivity and resistance assay (CSRA), originated in the
1950s [25]. There are different types of CSRAs such as the
adenosine triphosphate (ATP) assay, human tumor cloning
assay (HTCA), methylthiazolyl-diphenyl-tetrazolium bro-
mide (MTT) assay, extreme drug resistance (EDR) assay,
as well as assays utilizing drug-induced apoptosis as the
end point [24, 26, 27]. A high-impact HTCA study pub-
lished in 1978 was followed by decades of research from
various academic groups and a few commercial entities
with mixed results [28–31]. While other CSRA reviews
have been published previously [24, 26], this review will
focus on progress made during the most recent decade.
The value of CSRAs to inform effective treatment
selection for individual patients remains a compelling
clinical question and a highly debated topic among on-
cologists. While the advantages and disadvantages of var-
ious CSRA methods have been published, clinical
validations demonstrating association of assay results with
patient outcomes through prospective studies have the most
value. Several CSRA clinical validations have been
reported recently. A prospective histoculture drug response
assay (HDRA) study in advanced EOC patients (n = 104)
treated with carboplatin and paclitaxel after cytoreductive
surgery demonstrated a lower recurrence rate and extended
PFS, both of which were statistically significant, in the
HDRA-sensitive group as compared to the HDRA-resistant
group [32]. Another prospective study, utilizing an ATP-
based chemoresponse assay, evaluated response rate and
PFS in platinum-resistant recurrent EOC patients
(n = 180) randomized to assay-directed or physician’s
empiric therapy choice, demonstrating trends for improved
response rate and PFS for assay-informed treatment [33].
And, finally, a prospective study of 113 recurrent EOC
patients showed that patients whose treatment was deter-
mined by an ATP-based chemoresponse assay had statis-
tically longer PFS and higher overall response rates
compared with patients receiving physician’s-choice ther-
apy [34]. Numerous retrospective data have also been
published in the past decade, with the majority reporting
statistically significant associations between assay results
and clinical outcomes [35–37]. The results from these
various studies reasonably demonstrate the clinical poten-
tial of chemoresponse assays in both primary and recurrent
EOC.
Although several chemoresponse assays’ clinical valid-
ity and clinical utility have been evaluated in clinical trials,
there are currently only two assays commercially available
in the United States: the Microculture-Kinetic (MiCK)
assay (DiaTech Oncology, Franklin, TN) and the Chemo-
Fx assay (Precision Therapeutics, Inc., Pittsburgh, PA).
The MiCK assay is based on drug-induced apoptosis and
was originally developed in hematologic malignancies
where it was noted that chemotherapeutic drugs have the
ability to rapidly induce apoptosis in tumor cells in short-
term culture. The assay was later applied to solid tumors,
including breast, lung, and gynecologic malignancies [27,
38–41]. Clinical validation of the MiCK assay in 73 ovarian
cancer patients demonstrated that clinical treatment with the
assay-indicated ‘‘best’’ chemotherapy is an independent
predictor of OS in multivariate analysis of chemotherapy-
naı¨ve stage III or IV primary ovarian cancer patients [27]. A
clinical utility study of 44 cancer patients showed that on-
cologists used the MiCK assay to determine chemotherapy
selection in 28 patients (64 %) and did not use the assay in
treatment selection for the other 16 patients (36 %). The
median OS was 10.1 months for the assay-informed
patients vs. 4.1 months for the assay-uninformed patients
(p = 0.02). However, the 44 tumors in the study included a
variety of tissue types, such as breast and non-small lung
cancers; only two ovarian cancer tumors were included in
the study [38]. Therefore, the clinical validation and clinical
utility of this assay in ovarian cancer requires further
investigation. The ChemoFx chemoresponse assay has been
extensively evaluated in patients with ovarian cancer and
will be the focus of the remainder of this review.
ChemoFx
Assay process
ChemoFx is a chemoresponse assay that characterizes both
the sensitivity and resistance of a patient’s tumor to various
Clin Transl Oncol (2014) 16:761–769 763
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physician-selected, clinically applicable chemotherapy
treatments. It quantifies chemotherapy effect by direct
visualization and enumeration of live cells following
exposure to these treatments. The assay is performed in a
Clinical Laboratory Improvement Amendments (CLIA)
and New York State Department of Health (NYSDOH)
approved facility. The assay procedure is illustrated in
Fig. 1 and has been previously reported [42–46].
In contrast to other CSRAs, this chemoresponse assay is
characterized by several features that make it more repro-
ducible and clinically accessible.
• The assay uniquely insures that tumor cells are
proliferating prior to chemotherapy exposure, thereby
measuring treatment efficacy at halting proliferation
and/or killing tumor cells. This approach accommo-
dates the cell cycle-specific, cytostatic, and cytotoxic
natures of various chemotherapies.
• The assay’s primary culture process is optimized to
generate sufficient proliferating tumor cells for testing.
As a result, 9 out of 10 ovarian cancer samples meeting
the incoming sample criteria, such as sufficient sample
size and absence of microorganism contamination, are
successfully reported.
• The culture process favors epithelial tumor cell prolif-
eration and incorporates an immunocytochemistry
(ICC) step to insure that the majority of cells tested
are epithelial.
• The assay process is highly automated. Cell seeding
into microtiter plates, serial treatment dilution and
application, cell fixation, fluorescence staining, as well
as cell enumeration are performed using automated
liquid handling robotics, computer-assisted micros-
copy, and automated cell-counting algorithms and
software. The automated process strongly contributes
to the high throughput and reproducibility of the assay
[43].
• Lastly, this assay requires significantly less tissue (a
minimum of 35 mm3), as compared to historical assays.
Tumor tissue from surgical excision, biopsy, or para-
centesis is compatible, making the assay highly clin-
ically accessible [42].
Analytical and clinical validation
The analytical performance of this assay has been previ-
ously reported [42, 43, 46]. Heinzman et al. demonstrated a
coefficient of variation (CoV) of 3.6–4.6 % for SK-OV-3
cells treated with doxorubicin, across three operators and
9 days [42]. In addition to variability across operators and
days, process variability due to inter- and intraday stability
of the chemotherapeutic treatments has also been reported
[46]. The assay has demonstrated the necessary analytical
performance characteristics required by both CLIA and
NYSDOH.
Clinical validation of this assay has been the subject of
numerous studies in EOC. Gallion et al. demonstrated the
association of assay response with PFS in 256 EOC
patients. In patients with either an exact or partial match
between treatments assayed and those that were clinically
administered, the hazard ratio (HR) for progression in
patients clinically treated with an assay-resistant (R) vs.
assay-sensitive (S) treatment was 2.1 (95 % CI 1.2–3.6,
p = 0.01). In the subset of 135 patients with an exact
match, the HR for progression in patients clinically
administered an assay-R vs. assay-S treatment was 2.9
(95 % CI 1.4–6.3, p \ 0.01). The median PFS for patients
treated with R therapies was 9 and 14 months for those
treated with intermediate sensitive (IS) therapies. Further-
more, at the time of study completion with a median fol-
low-up time of 14.6 months, 60 % of patients treated with
S therapies remained relapse-free [45].
Herzog et al. subsequently reported an association
between assay response and OS in 192 patients with
advanced EOC following first-line platinum-based che-
motherapy. Median OS was 72.5, 48.6, and 28.2 months
for patients who were treated with agents reported as S, IS,














AJOG 2010 Sensitive group
Median OS 44 month 44 month 44 month 44 month 44 month 48 month 72.5 month
1-year 92 % 91 % 90 % 90 % 91 % 85 % 90 %
2-year 74 % 72 % 73 % 75 % 74 % 72 % 86 %
3-year 59 % 57 % 58 % 60 % 59 % 59 % 75 %
4-year 47 % 45 % 46 % 45 % 46 % 51 % 70 %
5-year 38 % 35 % 38 % 35 % 37 % 44 % 60 %
6-year 29 % NA 28 % 30 % 29 % 39 % 55 %
Annual OS rates in the four cohorts comprising the control arm are based on extrapolation of the published Kaplan–Meier survival curves [2–5,
45]
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and R, respectively (HR = 0.7, 95 % CI 0.50–0.97,
p = 0.03). Multivariate Cox regression analysis demon-
strated that the assay prediction of response to platinum
agents was a predictor of OS independent of other prog-
nostic factors of stage, age, and optimal debulking
(HR = 0.68, 95 % CI 0.49–0.95, p = 0.023) [44].
In another more recent observational study of 276
women with FIGO stage III-IV EOC cancer uniformly
treated with first-line carboplatin-/paclitaxel-based therapy,
patients with assay-R results for carboplatin were at
increased risk of disease progression (as defined by PFS)
compared with patients with S or IS assay results
(HR = 1.87, 95 % CI 1.29–2.70, p = 0.0009); these
results were consistent after controlling for clinical covar-
iates (HR = 1.71, 95 % CI 1.12–2.62, p = 0.013). Median
PFS for patients who were assay-R to carboplatin was 11.8
vs. 16.6 months for assay-IS and assay-S patients. This
study demonstrates that assay resistance to carboplatin is
associated with reduced PFS in EOC patients treated with
standard of care carboplatin/paclitaxel, supporting the
assay’s ability to identify platinum-resistant patients. Fur-
thermore, of those patients who were resistant to carbo-
platin in vitro, 59 % of them displayed assay sensitivity (S
or IS) to at least one other agent [48].
Finally, a prospective study of 262 women with recur-
rent or persistent EOC reported that patients treated with an
assay-S regimen experienced significantly improved PFS
(HR = 0.67, 95 % CI 0.50–0.91, p = 0.009) and OS
(HR = 0.61, 95 % CI 0.41–0.89, p = 0.010) compared
with those treated with assay-IS or assay-R regimens,
resulting in a 14-month improvement in median OS.
Assay-PFS association was consistent in both platinum-
sensitive and platinum-resistant tumors (HR: 0.71 and 0.66,
respectively) and was independent of other covariates
(HR = 0.66, 95 % CI 0.47–0.94, p = 0.020). Moreover,
the results indicated that more than 50 % of the patients
had at least one S therapy identified by the assay, whereas
only 25 % of them were empirically treated with an S drug,
suggesting that the number of patients potentially experi-
encing improved OS may more than double when physi-
cians reference the assay [49].
A further analysis of the 262 recurrent or persistent EOC
patients reported by Rutherford et al. [49] was presented at
the 2013 European Cancer Organization (ECCO) Biennial
Meeting and addressed the assay’s ability to function as a
predictive marker [50]. A prognostic assay identifies
patients likely to respond/not respond to (any) therapy,
while a predictive assay identifies a patient’s likely
response to specific therapies, which is particularly
important for individualized chemotherapy selection. Four
different analytical methods were used in the study to
assess the predictive value of the assay. These analyses
provide the evidence that this chemoresponse assay is a
predictive marker, demonstrating its ability to discern
specific therapies that are likely to be more effective
among multiple alternatives [50].
As briefly outlined earlier, a chemoresponse assay, such
as ChemoFx, is a panel of treatment markers, with the
assay result for each treatment evaluated functioning as a
distinct marker. When ordering the assay, a physician
selects each of the multiple treatments under consideration
for a given patient for inclusion in the assay. Clinically
validated chemotherapy regimens, consistent with guide-
lines such as NCCN, comprise the available treatment
choices.
Clinical trials designed to evaluate marker or assay
efficacy are fundamentally different than trials designed
to evaluate drug efficacy. Various different marker trial
designs have been extensively studied and reported in the
recent literature. However, discussion of effective marker
validation trial designs that are appropriate for multiple
markers/therapies to be assessed simultaneously (e.g.,
chemoresponse assays) remains very limited in the cur-
rent trial design literature. Marker validation trial designs
for this type of multiple markers/therapies assay may
vary, to some extent, from marker trial designs appro-
priate for a single molecular biomarker associated with
a single therapy (e.g., KRAS/panitumumab, EGFR/
erlotinib).
Primarily, three marker study designs have been out-
lined in the literature for marker validation: enrichment,
strategy, and stratified [51–53]. Marker negative patients
Fig. 1 ChemoFx assay process. ICC immunocytochemistry, AUC area under curve, S sensitive, IS intermediate sensitive, R resistant
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are excluded in the enrichment design, and thus, it is not
applicable to chemoresponse assay evaluation.
Historically, the strategy design, in many ways similar
to a standard drug trial design, has been considered the
‘‘gold standard’’ for marker validation as it attempts to
emulate what might occur in clinical practice. A variant of
the strategy design has been recommended by the Ameri-
can Society of Clinical Oncology (ASCO) and Blue Cross
Blue Shield (BCBS) Technical Evaluation Center (TEC)
Assessments of validations of chemoresponse assays [54,
55] date back to the mid 1990s. However, multiple recent
and updated marker trial design publications, including an
evaluation by the Center for Medical Technology Policy
(CMTP) in 2013 [56], indicate that the strategy design is
less than ideal for marker validation, in that it requires a
larger sample size and cannot distinguish between a more
effective treatment and marker efficacy, when compared to
alternate marker trial designs. Friedlin et al. show that the
required sample size for a strategy design can exceed
several thousand patients depending on the prevalence of
the marker in the study population, presenting a large
challenge in a small incidence/prevalence disease like
EOC. Further and specific to chemoresponse assays where
multiple markers are evaluated simultaneously, the pan-
resistant and pan-sensitive patients dilute the ability to
assess assay impact on patient outcome. Additionally,
overlapping treatments between study arms still further
increase the required sample size, rendering the strategy
approach essentially pragmatically infeasible. Finally, a
potential physician treatment bias or ‘‘learning effect’’ may
be associated with the strategy design. The strategy trial
design attempted by Cree et al. showed a trend toward
improved response rate and PFS in assay-informed patients
as compared to those treated with the physician’s empiric
choice, but did not achieve statistical significance. Cree
et al. asserted that physicians ‘‘learned’’ from the assay-
informed arm and began administering treatments similar
to those recommended for assay-informed patients to
patients in the physician-directed arm as the study pro-
gressed. Analysis confirmed this effect; in early physician-
choice arm patients, PFS was significantly shorter than that
in subsequent year patients [33].
The stratified design has been reported as more efficient,
capable of answering the relevant clinical questions, and
able to assess both prognostic and predictive marker
properties, which is often at issue with evaluations of
markers [52, 56, 57]. Friedlin et al. have concluded that
trial designs, such as the stratified design that use the
marker to guide analysis, but not treatment assignment
(i.e., blind or non-interventional designs), are recom-
mended for marker validation [52]. The stratified design
has been successfully implemented in multiple clinical
validations of clinical guideline recommended markers,
including KRAS, EGFR, Oncotype DX (Genomic Health,
Inc., Redwood City, CA, USA), and VeriStrat (Biodesix,
Boulder, CO, USA). The prospective clinical validation
trial for the ChemoFx assay required that both the prog-
nostic and predictive properties of the assay be evaluated
using an analytical method very similar to the stratified
approach [49, 50].
Clinical utility and economic analysis
An important aspect of clinical utility considers how use of
an assay or marker affects patient outcome in terms of
treatment selection, survival, and morbidity. Other con-
siderations include the impact of the assay or marker usage
on physician treatment plans as well as immediate and
downstream healthcare costs [57–59].
To further demonstrate the clinical utility of this che-
moresponse assay, we conducted a comparative analysis
based on a ‘‘two-arm’’ marker strategy approach. A
192-patient cohort, serving as the assay-informed arm [44],
was compared to a non-assay-informed (historical control)
arm, comprised of patients treated by non-assay-informed
physicians from four large cooperative group drug studies
in primary EOC, totaling more than 7,000 patients [2–46].
OS was the primary end point for comparison and analysis.
Patient characteristics in both the assay-informed and
control arms were similar with the exception that between
11 and 16 % more optimally debulked patients were
included in the multiple literature cohorts that comprise the
control arm (Table 1). Additionally, while the assay-
informed arm and the largest control arm cohort consisted
of only advanced stage patients [5, 44], the other three
control arm cohorts also included a small portion of earlier
stage patients. Based on traditionally accepted adverse
clinical variables, a worse prognosis was projected for the
assay-informed cohort given the greater proportion of late-
stage and sub-optimally debulked patients.
Despite worse prognostic clinical factors, patients in the
assay-informed arm experienced a 10 % improvement in
median OS compared with the literature-derived control
arm (48 vs. 44 months, respectively) [44]. Furthermore, at
study completion (6 years follow-up), 39 % of the assay-
informed patients were alive compared to 29 % of control
arm patients (Table 2).
Median OS for the assay-informed arm, stratified by
assay response category, was S = 72.5 (n = 20),
IS = 48.6 (n = 133), and R = 28.2 months (n = 39)
(Table 2; Fig. 2), representing a 28.5 month (72.5 vs. 44,
65 %) increased OS for patients treated with assay-S reg-
imens and a 15.8 month (28.2 vs. 44, 36 %) decreased OS
for patients treated with assay-R regimens, as compared to
the control arm. When comparing annual OS for assay-
informed patients treated with an S regimen to control arm
766 Clin Transl Oncol (2014) 16:761–769
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patients, 10–25 % more assay-informed patients were liv-
ing in years 2 thru 6. Notably, 55 % of assay-informed
patients treated with an S regimen were alive at year 6
compared to 29 % in the control arm, despite the disparity
in adverse clinical factors favoring the control arm
(Table 2).
An analysis of survival from patients in the control arm
cohorts [2–46] indicates that the various treatment regi-
mens had similar efficacy when therapies were randomly
assigned in phase III clinical trials [2–5, 44]. Therefore,
even though therapies from the same ‘‘pool’’ of approved
and recommended treatment options were administered to
patients in the comparative analysis, patients whose treat-
ment was assay-informed had improved survival when
compared to patients whose treatment was randomly
assigned. Furthermore, in the assay-informed arm, final
treatment decisions for patients were made by their phy-
sicians, and assays were used to assist treatment selections
in some cases and not in others [44]. It is therefore rational
to hypothesize that if physicians routinely had chemore-
sponse information available when choosing chemothera-
peutic regimens for patients with ovarian cancer, OS might
be further improved.
Average chemotherapy costs for patients with recurrent
ovarian cancer treated with or without use of the assay have
also been evaluated [60]. Results based on UBS Warburg
market share data demonstrated mean costs for chemo-
therapy treatment were $48,758 for patients treated
empirically (no assay), $33,187 for patients with assay
results available (65 % adhered to assay results), and
$23,986 for patients modeled to have 100 % adherence to
assay results. Spanning the median OS of 44 months, the
majority of EOC patients experience multiple episodes of
disease recurrence [6]. Therefore, treatment costs typically
include both surgery and multiple chemotherapy interven-
tions [61]. Considering that assay-informed treatment
selection may result in delayed cancer progression and
increased OS, if one or more of the multiple chemotherapy
interventions were delayed or avoided in assay-informed
patients, treatment costs may be reduced by the costs
associated with less effective chemotherapy regimens.
Use of chemoresponse assays during primary therapy
may help to identify patients with platinum-resistant dis-
ease, potentially allowing for consideration of alternate
clinically validated [5] or similarly appropriate [65–67]
treatments, as well as prognostic stratification of patients in
prospective clinical trials and/or modification of primary
therapies ‘‘off trial’’ such as the addition of bevacizumab or
other targeted therapies to standard carboplatin/paclitaxel
treatment [62–64]. Likewise, in the recurrent disease set-
ting where there is no single standard of care, CRSAs may
assist oncologists with prioritization of the various single-
agent therapies used with or without platinum therapies
[54–56]. Additionally, in both primary and recurrent EOC,
in the event of a severe drug reaction, physicians may
employ this assay to identify an effective (S or IS) therapy
with which to replace the toxic agent.
Conclusions
Despite several years of chemoresponse assay development
and clinical experience with these assays, studies have
largely been confined to single-institutional, retrospective
Fig. 2 Kaplan–Meier survival
curves comparing the control
arm cohort [5] (black) and the
assay-informed arm cohort [45].
Survival curves for the assay-
informed cohort were stratified
according to assay response
category of clinically
administered therapy
(S sensitive, green; IS
intermediate sensitive, light
green; R resistant, red)
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evaluations. Recent large, prospective, multi-site clinical
studies that correlate ChemoFx assay results with overall
and progression-free survival in both primary and recurrent
ovarian cancers indicate that the assay may offer significant
clinical benefit for patients, is predictive of treatment out-
comes, and is potentially economically beneficial by
reducing the chance that ineffective chemotherapy is
administered. This overview supports the inclusion of
chemoresponse assay results, along with other clinical
factors and biomarkers, to support the individualized
selection of effective chemotherapy agents for treatment of
patients with ovarian cancer.
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